RAB10: an Alzheimer's disease resilience locus and potential drug target

Clin Interv Aging. 2018 Dec 28:14:73-79. doi: 10.2147/CIA.S159148. eCollection 2019.


Alzheimer's disease (AD) is mainly a late-onset neurodegenerative disorder. Substantial efforts have been made to solve the complex genetic architecture of AD as a means to identify therapeutic targets. Unfortunately, to date, no disease-altering therapeutics have been developed. As therapeutics are likely to be most effective in the early stages of disease (ie, before the onset of symptoms), a recent focus of AD research has been the identification of protective factors that prevent disease. One example is the discovery of a rare variant in the 3'-UTR of RAB10 that is protective for AD. Here, we review the possible genetic, molecular, and functional role of RAB10 in AD and potential therapeutic approaches to target RAB10.

Keywords: APP; Alzheimer’s disease; GTPase; RAB10; resilience; retromer.

Publication types

  • Review

MeSH terms

  • 3' Untranslated Regions
  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / genetics*
  • Alzheimer Disease / metabolism*
  • Animals
  • Drug Discovery
  • Humans
  • Protective Factors
  • rab GTP-Binding Proteins / genetics*
  • rab GTP-Binding Proteins / metabolism*


  • 3' Untranslated Regions
  • Rab10 protein, human
  • rab GTP-Binding Proteins